Short-duration oral terbinafine for the treatment of tinea pedis in HIV-positive patients.

S. Smith, K. Houpt, Phoebe Rich, A. LaMarca, J. M. Weinberg, T. S. Alferez, E. Atillasoy, C. Opper

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Management of tinea pedis in patients who have the human immunodeficiency virus (HIV) is problematic; in those patients, dermatophytoses may be more difficult to treat than in the general population. This prospective, open-label, multicenter, randomized study evaluated the efficacy and safety of a short course of oral terbinafine for tinea pedis in patients who are HIV positive. Twenty-seven patients were randomized to receive oral terbinafine 250 mg once daily for 2 or 4 weeks; 17 patients with positive initial cultures and follow-up cultures were evaluable for efficacy at week 8. Mycological cure (defined as negative potassium hydroxide [KOH] microscopy and culture results) occurred in 47% (8) of patients; and modified mycological cure (defined as negative follow-up cultures) occurred in 65% (11) of patients. All 27 patients were evaluated for safety. Clinical cure (defined as minimal residual signs and symptoms) occurred in 82% (14) of patients. Oral terbinafine was well tolerated, indicating that regimens of 2 or 4 weeks are safe and effective for the treatment of tinea pedis in patients who are HIV positive.

Original languageEnglish (US)
Pages (from-to)30-39
Number of pages10
JournalCutis; cutaneous medicine for the practitioner
Volume68
Issue number1 Suppl
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

terbinafine
Tinea Pedis
HIV
Therapeutics
Safety
Tinea

ASJC Scopus subject areas

  • Dermatology

Cite this

Smith, S., Houpt, K., Rich, P., LaMarca, A., Weinberg, J. M., Alferez, T. S., ... Opper, C. (2001). Short-duration oral terbinafine for the treatment of tinea pedis in HIV-positive patients. Cutis; cutaneous medicine for the practitioner, 68(1 Suppl), 30-39.

Short-duration oral terbinafine for the treatment of tinea pedis in HIV-positive patients. / Smith, S.; Houpt, K.; Rich, Phoebe; LaMarca, A.; Weinberg, J. M.; Alferez, T. S.; Atillasoy, E.; Opper, C.

In: Cutis; cutaneous medicine for the practitioner, Vol. 68, No. 1 Suppl, 01.01.2001, p. 30-39.

Research output: Contribution to journalArticle

Smith, S, Houpt, K, Rich, P, LaMarca, A, Weinberg, JM, Alferez, TS, Atillasoy, E & Opper, C 2001, 'Short-duration oral terbinafine for the treatment of tinea pedis in HIV-positive patients.', Cutis; cutaneous medicine for the practitioner, vol. 68, no. 1 Suppl, pp. 30-39.
Smith, S. ; Houpt, K. ; Rich, Phoebe ; LaMarca, A. ; Weinberg, J. M. ; Alferez, T. S. ; Atillasoy, E. ; Opper, C. / Short-duration oral terbinafine for the treatment of tinea pedis in HIV-positive patients. In: Cutis; cutaneous medicine for the practitioner. 2001 ; Vol. 68, No. 1 Suppl. pp. 30-39.
@article{facc0962e58b4af4bc09d1df4f295677,
title = "Short-duration oral terbinafine for the treatment of tinea pedis in HIV-positive patients.",
abstract = "Management of tinea pedis in patients who have the human immunodeficiency virus (HIV) is problematic; in those patients, dermatophytoses may be more difficult to treat than in the general population. This prospective, open-label, multicenter, randomized study evaluated the efficacy and safety of a short course of oral terbinafine for tinea pedis in patients who are HIV positive. Twenty-seven patients were randomized to receive oral terbinafine 250 mg once daily for 2 or 4 weeks; 17 patients with positive initial cultures and follow-up cultures were evaluable for efficacy at week 8. Mycological cure (defined as negative potassium hydroxide [KOH] microscopy and culture results) occurred in 47{\%} (8) of patients; and modified mycological cure (defined as negative follow-up cultures) occurred in 65{\%} (11) of patients. All 27 patients were evaluated for safety. Clinical cure (defined as minimal residual signs and symptoms) occurred in 82{\%} (14) of patients. Oral terbinafine was well tolerated, indicating that regimens of 2 or 4 weeks are safe and effective for the treatment of tinea pedis in patients who are HIV positive.",
author = "S. Smith and K. Houpt and Phoebe Rich and A. LaMarca and Weinberg, {J. M.} and Alferez, {T. S.} and E. Atillasoy and C. Opper",
year = "2001",
month = "1",
day = "1",
language = "English (US)",
volume = "68",
pages = "30--39",
journal = "Cutis",
issn = "0011-4162",
publisher = "Quadrant Healthcom Inc.",
number = "1 Suppl",

}

TY - JOUR

T1 - Short-duration oral terbinafine for the treatment of tinea pedis in HIV-positive patients.

AU - Smith, S.

AU - Houpt, K.

AU - Rich, Phoebe

AU - LaMarca, A.

AU - Weinberg, J. M.

AU - Alferez, T. S.

AU - Atillasoy, E.

AU - Opper, C.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Management of tinea pedis in patients who have the human immunodeficiency virus (HIV) is problematic; in those patients, dermatophytoses may be more difficult to treat than in the general population. This prospective, open-label, multicenter, randomized study evaluated the efficacy and safety of a short course of oral terbinafine for tinea pedis in patients who are HIV positive. Twenty-seven patients were randomized to receive oral terbinafine 250 mg once daily for 2 or 4 weeks; 17 patients with positive initial cultures and follow-up cultures were evaluable for efficacy at week 8. Mycological cure (defined as negative potassium hydroxide [KOH] microscopy and culture results) occurred in 47% (8) of patients; and modified mycological cure (defined as negative follow-up cultures) occurred in 65% (11) of patients. All 27 patients were evaluated for safety. Clinical cure (defined as minimal residual signs and symptoms) occurred in 82% (14) of patients. Oral terbinafine was well tolerated, indicating that regimens of 2 or 4 weeks are safe and effective for the treatment of tinea pedis in patients who are HIV positive.

AB - Management of tinea pedis in patients who have the human immunodeficiency virus (HIV) is problematic; in those patients, dermatophytoses may be more difficult to treat than in the general population. This prospective, open-label, multicenter, randomized study evaluated the efficacy and safety of a short course of oral terbinafine for tinea pedis in patients who are HIV positive. Twenty-seven patients were randomized to receive oral terbinafine 250 mg once daily for 2 or 4 weeks; 17 patients with positive initial cultures and follow-up cultures were evaluable for efficacy at week 8. Mycological cure (defined as negative potassium hydroxide [KOH] microscopy and culture results) occurred in 47% (8) of patients; and modified mycological cure (defined as negative follow-up cultures) occurred in 65% (11) of patients. All 27 patients were evaluated for safety. Clinical cure (defined as minimal residual signs and symptoms) occurred in 82% (14) of patients. Oral terbinafine was well tolerated, indicating that regimens of 2 or 4 weeks are safe and effective for the treatment of tinea pedis in patients who are HIV positive.

UR - http://www.scopus.com/inward/record.url?scp=0035409633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035409633&partnerID=8YFLogxK

M3 - Article

C2 - 11499332

AN - SCOPUS:0035409633

VL - 68

SP - 30

EP - 39

JO - Cutis

JF - Cutis

SN - 0011-4162

IS - 1 Suppl

ER -